why Fate Therapeutics Inc. [FATE] is a Good Choice for Investors After New Price Target of $8.31

Fate Therapeutics Inc. [NASDAQ: FATE] jumped around 0.59 points on Thursday, while shares priced at $6.20 at the close of the session, up 10.52%. The company report on March 3, 2023 that Fate Therapeutics to Present at Upcoming March Investor Conferences.

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


43rd Annual TD Cowen Health Care Conference on Wednesday, March 8, 2023 at 12:50 PM ET in Boston, Massachusetts.

Fate Therapeutics Inc. stock is now -38.55% down from its year-to-date (YTD) trading value. FATE Stock saw the intraday high of $6.29 and lowest of $5.64 per share. The company’s 52-week high price is 39.24, which means current price is +54.23% above from all time high which was touched on 01/05/23.

Compared to the average trading volume of 2.74M shares, FATE reached a trading volume of 3671292 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Fate Therapeutics Inc. [FATE]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $8.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wells Fargo have made an estimate for Fate Therapeutics Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on March 27, 2023. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $115 to $7. The new note on the price target was released on January 24, 2023, representing the official price target for Fate Therapeutics Inc. stock. Previously, the target price had yet another drop from $42 to $7, while Wedbush kept a Neutral rating on FATE stock. On January 06, 2023, analysts decreased their price target for FATE shares from 46 to 7.

The Average True Range (ATR) for Fate Therapeutics Inc. is set at 0.39, with the Price to Sales ratio for FATE stock in the period of the last 12 months amounting to 5.94. The Price to Book ratio for the last quarter was 1.24, with the Price to Cash per share for the same quarter was set at 4.73.

How has FATE stock performed recently?

Fate Therapeutics Inc. [FATE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.73. With this latest performance, FATE shares gained by 13.14% in over the last four-week period, additionally sinking by -70.38% over the last 6 months – not to mention a drop of -82.70% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 58.40, with the RSI for the last a single of trading hit 64.61, and the three-weeks RSI is set at 52.33 for Fate Therapeutics Inc. [FATE]. The present Moving Average for the last 50 days of trading for this stock 5.87, while it was recorded at 5.76 for the last single week of trading, and 17.63 for the last 200 days.

Fate Therapeutics Inc. [FATE]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Fate Therapeutics Inc. [FATE] shares currently have an operating margin of -320.23 and a Gross Margin at +85.71. Fate Therapeutics Inc.’s Net Margin is presently recorded at -292.55.

Return on Total Capital for FATE is now -44.47, given the latest momentum, and Return on Invested Capital for the company is -40.96. Return on Equity for this stock declined to -48.46, with Return on Assets sitting at -34.63. When it comes to the capital structure of this company, Fate Therapeutics Inc. [FATE] has a Total Debt to Total Equity ratio set at 22.59. Additionally, FATE Total Debt to Total Capital is recorded at 18.43, with Total Debt to Total Assets ending up at 15.50. Long-Term Debt to Equity for the company is recorded at 21.43, with the Long-Term Debt to Total Capital now at 17.48.

Reflecting on the efficiency of the workforce at the company, Fate Therapeutics Inc. [FATE] managed to generate an average of -$511,290 per employee. Receivables Turnover for the company is 4.08 with a Total Asset Turnover recorded at a value of 0.12.Fate Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.40.

Insider trade positions for Fate Therapeutics Inc. [FATE]

There are presently around $593 million, in the hands of institutional investors. The top three institutional holders of FATE stocks are: REDMILE GROUP, LLC with ownership of 12,957,222, which is approximately 0% of the company’s market cap and around 1.00% of the total institutional ownership; BLACKROCK INC., holding 9,726,224 shares of the stock with an approximate value of $54.56 million in FATE stocks shares; and VANGUARD GROUP INC, currently with $44.73 million in FATE stock with ownership of nearly 2.016% of the company’s market capitalization.

Positions in Fate Therapeutics Inc. stocks held by institutional investors increased at the end of Wednesday and at the time of the Wednesday reporting period, where 132 institutional holders increased their position in Fate Therapeutics Inc. [NASDAQ:FATE] by around 19,461,742 shares. Additionally, 103 investors decreased positions by around 21,375,764 shares, while 36 investors held positions by with 64,909,894 shares. The mentioned changes placed institutional holdings at 105,747,400 shares, according to the latest SEC report filing. FATE stock had 35 new institutional investments in for a total of 1,918,554 shares, while 45 institutional investors sold positions of 4,102,480 shares during the same period.


Please enter your comment!
Please enter your name here